Benefits and pitfalls of cardiovascular medication in seniors

Wiener Klinische Wochenschrift

Volumn 125, Issue 15-16, 2013, Pages 425-436

  Kubesova, Hana Matejovska ^a   Weber, Pavel ^a   Meluzinova, Hana ^a   Bielakova, Katarina ^a   Matejovsky, Jan ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

blockers; Angiotensin converting enzyme inhibitors; Antiaggregants; Calcium blockers; Digoxin; Diuretics; Medical interactions; Pharmacotherapy in the elderly; Statins; Unwanted side effects

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLYCOSIDE; AMIODARONE; ANALGESIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BISOPROLOL; CARDIOVASCULAR AGENT; CARVEDILOL; CEPHALOSPORIN; CITALOPRAM; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FUROSEMIDE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LITHIUM; MACROLIDE; NICOTINIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; SOTALOL; TICLOPIDINE; UNINDEXED DRUG; WARFARIN;

ANGINA PECTORIS; ANTICOAGULANT THERAPY; ATAXIA; BLEEDING; BLOOD PRESSURE; BRADYCARDIA; CARDIOVASCULAR MORTALITY; COUGHING; DEPRESSION; DIGITALIS INTOXICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG OVERDOSE; DRUG SAFETY; DYSPEPSIA; ELECTROLYTE DISTURBANCE; FAINTNESS; FALLING; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; GRAPEFRUIT JUICE; HEADACHE; HEARING DISORDER; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INFECTION; INSOMNIA; KIDNEY DYSFUNCTION; LUNG FIBROSIS; MEMORY DISORDER; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; OBSTRUCTIVE JAUNDICE; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PNEUMONIA; PRACTICE GUIDELINE; REVIEW; RHABDOMYOLYSIS; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; SLEEP DISORDER; TACHYCARDIA; TORSADE DES POINTES; TREMOR; VERTIGO;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84883451535     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-013-0395-2     Document Type: Review

References (69)

1. Kalvach Z, Zadak Z, Jirak R, et al. Geriatrics a gerontology. Praha: Grada publishing a.s.; 2004 (ISBN 80-247-0548-6).
2. Topinkova E. Geriatrics for practice. 1. vyd. Praha: Galen; 2005. S. 270.
3. Fialova D, Topinkova E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA. 2005;293(11):1348-58.
4. Kubesova H, Holik J, Bogrova I, et al. The influence of new scientific information on the treatment of elderly patients in general practice. Acta Medica Austriaca, od 2001;52-6, (5 s. ISSN 0303-8173).
5. Kubesova H, Holik J, Weber P, et al. Drug consumption and risks of polypharmacotherapy in seniors. Cas Lek Ces. 2006;9:708-12.
6. Zed PJ, Abu-Laban RJ, Balen RM. Incidence, severity and preventability of medication-related visits to emergency department: a prospective study. CMAJ. 2008;178(12):1563-9.
7. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck J. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med. 1991;151:1825-32.
8. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med. 1997;157:1531-6.
9. Mann E, Böhmdorfer B, Frühwald T, et al. Potentially inappropriate medication in geriatric patients: the Austrian consensus panel list. Wien Klin Wochenschr. 2012 Mar;124(5-6):160-9 (Epub 2011 Dec 2).
10. Kubesova H, Weber P, Kala P, et al. Acute coronary syndrome in seniors. Ces Ger Rev. 2008;6(3):41-6.
11. Matejovsky J. Complex evaluation of czech seniors living in their own environment. Diploma thesis, Faculty of st. Agnes, Bratislava, Slovakia, 2007, 107p.
12. Hemmelgarn BR, Chen G, Walker R, et al. Trends in antihypertensive drug prescriptions and physician visits between 1996 and 2006. Can J Cardiol. 2008;24(6):507-12.
13. Blakley BW, Gulati H. Identifying drugs that cause dizziness. J Otolaryngol. 2008;37(1):11-5.
14. Konopa J, Bullo B, Rutkowski B. Life threatening drug-induced hyperkalemia - case report. Pol Arch Med Wewm. 2006;115(3):238-42.
15. Summary of Product Characteristics. The official document of State Institute for Drug Control. http://www.sukl.cz/download/spc/SPC31490.doc.
16. Pilote L, Abrahamovicz M, Eisenberg M, et al. Effect of different angiotensin-converting enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ. 2008;178(10):1303-11.
17. Masunari N, Fujiwara S, Nakata Y, et al. Effect of angiotensin converting enzyme inhibitor and benzodiazepine intake on bone loss in older Japanese. Hiroshima J Med Sci. 2008;57(1):17-25.
18. Flammer AJ, Sudano I, Hermann F, et al. Angiotensin converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation. 2008;117(17):2262-9.
19. Werner C, Baumruckel M, Teo KK, et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patients selection. Clin Res Cardiol. 2008;5:305-11.
20. Recommendation of Czech cardiology association for diagnostics and treatment of cardiac failure. Cor et Vasa. 2007;49(1):K5-34 (Suppl. Cor Vasa 2007;49(11):75-104).
21. Tadevosyan A, Maclaughlin EJ, Karamyan VT. Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes. Patient Relat Outcome Meas. 2011 Jul;2:27-39 (Epub 2011 Jan 25).
22. Toyama T, Sato C, Koyama K. Olmesartan improves coronary flow reserve of hypertensive patients using coronary magnetic resonance imaging compared with amlodipine. Cardiology. 2012;122(4):230-6 (Epub 2012 Aug 14).
23. Matsui T, Yamagishi S, Takeuchi M. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res. 2010 Jan;61(1):34-9 (Epub 2009 Jul 25).
24. Kahn R, Robertson RM, Smith R, et al. The impact of prevention on reducing the burden of cardiovascular disease. Circulation. 2008;118(7):218-22.
25. Vekasi J, Koltai K, Gaal V, et al. The effect of aspirin on hemorheological parameters of patients with diabetic retinopathy. Clin Hemorheol Microcirc. 2008;39(1-4):385-9.
26. Summary of Product Characteristics. The official document of State Institute for Drug Control. http://www.sukl.cz/download/spc/SPC99741.doc.
27. Juby AG, Davis P. Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Clin Rheumatol. 2008;27(7):835-42.
28. Summary of Product Characteristics. The official document of State Institute for Drug Control. http://www.sukl.cz/download/spc/SPC35444.doc.
29. Nagata Y, Inomata JI, Kinoshita M. Impact of proton pump inhibitors or famotidine on the antiplatelet actions during dual-antiplatelet therapy in Japanese patients. Cardiovasc Interv Ther. 2012 Aug 11 (Epub ahead of print).
30. Jaspers Focks J, Brouwer MA, Oijen MG van. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart. 2013;99(8):520-7.
31. Macaione F, Montaina C, Evola S. Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation. ISRN Cardiol. 2012;2012:692761 (Epub 2012 Jun 27).
32. Summary of Product Characteristics. The official document of State Institute for Drug Control http://www.sukl.cz/download/spc/SPC26521.doc.
33. Arvanitakis Z, Grodstein F, Bienias JL, et al. Relation of NSAIDs to incident, change in cognitive function and AD patology. Neurology. 2008;70(23):2219-25.
34. Szekely CA, Green RC, Breitner JC, et al. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology. 2008;70(24):2291-8.
35. Cleland JG, Coletta AP, Yassin A, et al. Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT. Eur J Heart Fail. 2009 Dec;11(12):1214-9.
36. Vojacek J. Results of RE-LY study promise more effective, simplier and safer prevention of embolic complications in patients with non valvular atrial fibrillation. Vnitr Lek. 2010;55(11):1085-8.
37. Weltermann A, Brodmann M, Domanovits H, et al. Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. Wien Klin Wochenschr. 2012 May;124(9-10):340-7 (Epub 2012 May 11).
38. Gallagher A, Ritbrock S, Plomb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Throm Hemost. 2008;6:913-9.
39. Guidelines for the management of atrial fibrillation. ESC guidelines. Eur Heart J. 2010;31:2369-429.
40. Onalan O, Cumurcu BE, Bekar L, et al. Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. Mayo Clin Proc. 2008;83(5):595-9.
41. Astrolm-Lilja C, Odeberg JM, Ekman E, et al. Drug-induces torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2008;17(6):587-92.
42. Galinier M, Emeriau JP. Prescribing Beta-blockers in elderly patients with heart failure. Presse Med. 2008;37(6 Pt 2):1047-54.
43. Cleland JGF, Coletta AP, Torabi A, Clark AL. Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD and Signal HF. Eur J Heart Fail. 2009;11(8):802-5.
44. Rector TS, Nand IS, Nelson DB, et al. Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure. J Am Geriatr Soc. 2008;56(6):1021-7.
45. Summary of Product Characteristics. The official document of State Institute for Drug Control. http://www.sukl.cz/download/spc/SPC28950.doc.
46. Schindler K, Schima W, Kaliman JF. Cryptogenic organizing pneumonia due to amiodarone: long-term follow-up after corticosteroid treatment. Wien Klin Wochenschr. 2010 Aug;122(15-16):511-4 (Epub 2010 Aug 2).
47. Zgazarova S, Jedlickova H, Vasku V. Unwanted skin effects of amiodaron. Vnitr Lek. 2009;55(10):976-80.
48. Summary of Product Characteristics. The official document of State Institute for Drug Control. http://www.sukl.cz/download/spc/SPC33520.doc.
49. De Ferrari GM, Dusi V. Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012;11(6):1023-45.
50. Said SM, Esperer HD, Kluba K, et al. Efficacy and safety profile of dronedarone in clinical practice. Results of the Magdeburg Dronedarone Registry (MADRE study). Int J Cardiol. 2012 Jul 9 (Epub ahead of print).
51. Manderbacka K, Keskimaki I, Reunanen A, et al. Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients. Int J Equity Health. 2008;7(1):16-20.
52. Pretnar-Oblak J, Sebestjan M, Sabovic M. Statin treatment improves cerebral more than systemic endothelial dysfunction in patiens with arterial hypertension. Am J Hypertens. 2008;21(6):674-8.
53. Foody JM, Joyce AT, Rudolph AE, et al. Persistence of atorvastatin and simvastatin in patients with and without prior cardiovasculat diseases: a US managed care study. Curr Med Res Opin. 2008;24(7):1987-2000.
54. Pella D. Statin myopathy - rarity or reality? Vnitr Lek. 2010;9:853-7.
55. Föger B, Patsch JR. LDL-cholesterol in secondary prevention: goal-attainment in patients on lipid-lowering drugs in private practice and in hospitals in Austria (ZIEL). Wien Klin Wochenschr. 2011 Jan;123(1-2):21-7 (Epub 2010 Dec 20).
56. Drexel H, Chazelle F, Fauer C, et al. Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DY Slipidemia International Study (DYSIS). Wien Klin Wochenschr. 2011 Oct;123(19-20):611-7 (Epub 2011 Sep 29).
57. Pregelj P. Involvement of cholesterol in the pathogenesis of Alzheimer's disease: Role of statins. Psychiatr Danub. 2008;20(2):162-7.
58. Duron E, Hanon O. Vascular risk factors, cognitive decline and dementia. Vascular Health Risk Manag. 2008;4(2):363-81.
59. Kevelaitiene S, Slapikas R. A new approach to the treatment of dyslipidemia. Medicina (Kaunas). 2008; 44(5):407-13.
60. Goldstein MR, Mscitelli L, Pezzeta F. The double-edged sword of statin immunomodulation. Int J Cardiol. 2008;5:432-36.
61. Hirooka Y, Komara Y, Sagara Y, et al. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens. 2008;30(3):267-76.
62. Summary of Product Characteristics. The official document of State Institute for Drug Control. http://www.sukl.cz/download/spc/SPC78304.doc.
63. Summary of Product Characteristics. The official document of State Institute for Drug Control http://www.sukl.cz/download/spc/SPC33033.doc.
64. Kudoh T, Nagawaga T, Nawaga I. Additional small amounts of diuretics improve blood pressure control at low cost without disadvantages in blood sugar metabolism. Hypertens Res. 2008;31(3):455-62.
65. Spinar J, Soucek M. Rewieved recommendations for diagnostics and treatment of hypertension. Vnitr Lek. 2010;56(2):157-61.
66. Summary of Product Characteristics. The official document of State Institute for Drug Control. http://www.sukl.cz/download/spc/SPC12541.doc.
67. Oelze M, Knorr M, Kröller-Schön S, et al. Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression. Eur Heart J. 2012 May 3 (Epub ahead of print).
68. Summary of Product Characteristics. The official document of State Institute for Drug Control http://www.sukl.cz/download/spc/SPC98120.doc.
69. Summary of Product Characteristics. The official document of State Institute for Drug Control http://www.sukl.cz/download/spc/SPC19790.doc.